BeiGene

It's been another brutal week for already beaten-down Chinese tech stocks amid renewed fears of a mass exodus of ADRs from U.S. exchanges.

BeiGene is a commercial-stage biotechnology company specializing in developing cancer immunotherapies. While it has been capitalizing on strong structural tailwinds for medical research and development in recent years, there are many threats investors should…

Aditya Raghunath examines four Asian stocks that are flying under the radar, but can be top bets for 2022 and beyond.